Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.65 USD
+0.02 (0.17%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.42 -0.23 (-1.97%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ROIV 11.65 +0.02(0.17%)
Will ROIV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Other News for ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide ...
Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News
Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan
What Does the Market Think About Roivant Sciences?
See How Roivant Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity